In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2021.0008, Zeyi Cheng, Miaomiao Qi, Chengyuan Zhang and Yanxia Mao from Sichuan University, Sichuan, China, Second Hospital of Lanzhou University, Lanzhou, China and The Second Medical School of Lanzhou University, Lanzhou, China consider myocardial fibrosis in the pathogenesis, diagnosis, and treatment of hypertrophic cardiomyopathy.
The authors review the application of myocardial fibrosis in the diagnosis and treatment of HCM, focusing on research progress and the application of magnetic resonance imaging on the basis of the characteristics of fibrosis in the diagnosis and prognosis of HCM.
Hypertrophic cardiomyopathy (HCM) is a type of hereditary cardiomyopathy caused by gene mutation. Its histological features include cardiomyocyte hypertrophy and disarray as well as myocardial fibrosis. Gene mutation, abnormal signal transduction, and abnormal energy metabolism are considered the main mechanisms of myocardial fibrosis. There is a strong correlation between myocardial fibrosis and the occurrence, development, and prognosis of HCM.
###
Citation information: Myocardial Fibrosis in the Pathogenesis, Diagnosis, and Treatment of Hypertrophic Cardiomyopathy, Zeyi Cheng, Miaomiao Qi, Chengyuan Zhang and Yanxia Mao, Cardiovasc. Innov. App., 2021, https://doi.org/10.15212/CVIA.2021.0008
Keywords: Hypertrophic cardiomyopathy; myocardial fibrosis
CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. CVIA is indexed in the EMBASE, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.
Journal
Cardiovascular Innovations and Applications